ReviewNPJ breast cancer2023

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.

Jun Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.